April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Author Affiliations & Notes
  • Claudia Acosta
    INIO, Medellin, Colombia
    CLOFAN, Medellin, Colombia
  • Carolina Sardi
    INIO, Medellin, Colombia
    CLOFAN, Medellin, Colombia
  • Juan Fernando Pelaez
    INIO, Medellin, Colombia
    CLOFAN, Medellin, Colombia
  • Footnotes
    Commercial Relationships Claudia Acosta, None; Carolina Sardi, None; Juan Fernando Pelaez, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 244. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Claudia Acosta, Carolina Sardi, Juan Fernando Pelaez; CENTRAL CHOROIDAL THICKNESS MEASURED BY EDI OCT IN SUBJECTS UNDER CHRONIC TREATMENT WITH INTRAVITREAL ANTI-VEGF.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):244.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To measure macular choroidal thickness (CT) and describe EDI OCT characteristics in patients with Neovascular AMD who underwent multiple intravitreal injections of anti-VEGF agents, and to compare it with Early AMD eyes, and healthy eyes,

Methods: This is an age-matched, sex-matched, case-control, cross-sectional study. A total of 74 eyes of 58 patients were evaluated. 21 eyes with Neovascular AMD and chronic anti-angiogenic intravitreal treatment (>10 injections in a 30 month period), 21 eyes with Early AMD and 32 eyes of healthy volunteers underwent SD-OCT (RTVue) with EDI technique. The average choroidal thickness (CT) was compared with the average CT value of an (age-matched, sex-matched), early AMD group and a healthy control group. A description of the morphological findings was done. Univariate linear regression analyses were perform to evaluate choroidal thickness with age, gender, BCVA and AMD diagnosis and treatment.

Results: After controlling for age differences the number of Anti VEGF injections showed no statistically significant correlation with macular choroidal thickness (P=0,689). Among different covariates age was associated with CT (P<0.05) only in the healthy patients group, gender showed not significant association with CT in AMD groups, it was statistically significant only on the healthy group (P= 0.008). There was a difference in CT in the three groups but it was not statistically significant (P=0.064), it only show a significant difference (P<0.001) between the Early AMD and the healthy group Healthy subjects had significant thicker Choridal Measurements (234.9 μc CI 95%= 201.5- 268.2) than the other 2 groups; Patients of Neoavascular AMD showed thicker choroids (175.07 μc CI 95% =139.3-210.8) compared with Early AMD (126.3μc CI 95%= 94.9-157.6). The macular CT value was uneven in patients with Neoavascular AMD, but it was even in patients with Early AMD and healthy subjects, showing a linear distribution.

Conclusions: We found no correlation between the number anti VEGF injections and CT, it support the concept that anti-VEGF applications do not affect CT. In accordance to what other studies had indicated. In Healthy subjects macular CT value in patients with ages between 75-91 years is significant lower than macular CT value describe in other studies, there is not know the expected CT value for this age group, and other studies are needed.

Keywords: 585 macula/fovea • 552 imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • 688 retina  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.